12.10.19
A randomized, double-blind study published in the European Journal of Nutrition has demonstrated that AquaCelle, a patented self-micro-emulsifying delivery system (SMEDS), increased total absorption (AUC0-24hrs) of omega-3 (EPA and DHA) ethyl esters (EE), in humans, by six-fold compared to the control.
The study measured the uptake of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) EE over 24 hours in healthy adults under low-fat diet restrictions. Participants were randomized into two groups, receiving either the SMEDS AquaCelle fish oil formulation or the unformulated fish oil EE. The novel delivery system demonstrated a significant improvement in the oral absorption of omega-3 fatty acids without requiring a high-fat meal.
“It is commonly known that omega-3 absorption is best achieved with a high-fat meal. However, because many individuals require low-fat diet restrictions, oral bioavailability is incomplete and requires higher doses,” said George Kokkinis, co-founder/technical director at Pharmako Biotechnologies. “This study highlights the superiority of AquaCelle as a delivery system for significantly improved absorption of lipophilic ingredients.”
The AquaCelle technology is customizable to optimize bioavailability and dosage formats of several diverse, active ingredients. AquaCelle has more than 10 human pharmacokinetic and clinical studies underway and is also validated through laser light obscuration and dynamic light scattering (DLS) analysis. Additionally, AquaCelle can be formulated for use in multiple product sectors, including nutraceutical, cosmeceutical, pharmaceutical, food and beverage, as well as pet and veterinary applications.
“We are thrilled about the results of our technology. Omega-3s have many health benefits and reducing the relevant dose or improving its efficacy provides great benefits to both the manufacturer and the end consumer, said Eric Meppem, co-Founder/technical director at Pharmako Biotechnologies.
Pharmako is a science based Australian company specializing in innovation and unique product development. Gencor serves as its American partner and distributor.
The study measured the uptake of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) EE over 24 hours in healthy adults under low-fat diet restrictions. Participants were randomized into two groups, receiving either the SMEDS AquaCelle fish oil formulation or the unformulated fish oil EE. The novel delivery system demonstrated a significant improvement in the oral absorption of omega-3 fatty acids without requiring a high-fat meal.
“It is commonly known that omega-3 absorption is best achieved with a high-fat meal. However, because many individuals require low-fat diet restrictions, oral bioavailability is incomplete and requires higher doses,” said George Kokkinis, co-founder/technical director at Pharmako Biotechnologies. “This study highlights the superiority of AquaCelle as a delivery system for significantly improved absorption of lipophilic ingredients.”
The AquaCelle technology is customizable to optimize bioavailability and dosage formats of several diverse, active ingredients. AquaCelle has more than 10 human pharmacokinetic and clinical studies underway and is also validated through laser light obscuration and dynamic light scattering (DLS) analysis. Additionally, AquaCelle can be formulated for use in multiple product sectors, including nutraceutical, cosmeceutical, pharmaceutical, food and beverage, as well as pet and veterinary applications.
“We are thrilled about the results of our technology. Omega-3s have many health benefits and reducing the relevant dose or improving its efficacy provides great benefits to both the manufacturer and the end consumer, said Eric Meppem, co-Founder/technical director at Pharmako Biotechnologies.
Pharmako is a science based Australian company specializing in innovation and unique product development. Gencor serves as its American partner and distributor.
